Home » Thought Leadership » Page 6

Thought Leadership

Read our insights and commentary about industry news and innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 30 posts
May 3, 2019 | Videos

What’s Keeping Payers Up at Night?

US Market Access Trends: CBPartners' Andrew Gould asks a panel of US payers which market access challenges are currently keeping them up at night.

May 1, 2019 | Blog

Alzheimer’s Disease Clinical Trials: Where Do We Go Now?

PART II of CBPartners' CNS series:

US and Canada flags
February 21, 2019 | Blog

Vermont’s Drug Importation: Rubber, Meet Road

Vermont’s fledgling drug importation law has undergone preliminary savings analysis, with uninspiring projections of a 3.8% drug cost savings rate. CBPartners evaluates the real impact of this new policy.

September 9, 2018 | Blog

Evolving Reimbursement Dynamics in China

When the engine of innovation gets the green light of marketing authorisation, it is typically first in the USA, and sometimes for the EMA’s (European Medicines Agency) jurisdiction over much of Europe. Unfortunately, China is too often one the last markets among the major and highest-tier of emerging markets to be considered for broad patient access. CBPartners explores the evolving reimbursement dynamics in China.

September 17, 2017 | Blog

Does the Fate of MS Pricing Lie in the Hands of Politicians or Manufacturers?

Yet another drug pricing debate has started to brew in the USA, with its epicentre right in DC. Two Democratic members of the US House (Elijah Cummings (D-MD) and Peter Welch (D-VT)), announced that they are launching an investigation into the pricing of disease-modifying treatments for multiple sclerosis (MS). CBPartners investigates MS pricing in the political context.